Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Panminerva Medica|June 2, 2018
Hepatitis C virus-induced hepatocellular carcinoma: a narrative reviewMaja Ružić, Rinaldo Pellicano, Milotka Fabri, et al.Medicinski Pregled|August 13, 2002
[Use of antibiotics in general practice and at the Clinic for Infectious Diseases]Sandra Stefan-Mikić, Ana Sabo, Ana Gobor-Fodor, et al.Journal of Chemotherapy (Florence, Italy)|March 14, 2014
Treatment of acute hepatitis C in breast cancer patient: a case reportGorana Matovina-Brko, Maja Ruzic, Milotka Fabri, et al.Mediterranean Journal of Hematology and Infectious Diseases|September 16, 2021
Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible?Maja Ružić, Natalija Rajić, Milotka Fabri, et al.Srpski Arhiv Za Celokupno Lekarstvo|April 8, 2015
Boceprevir in genotype 1 chronic hepatitis C: first experiences in SerbiaJasmina Simonović Babić, Ksenija Bojović, Milotka Fabri, et al.Science in China. Series C, Life Sciences|November 14, 2009
Leptospirosis distribution related to freshwater habitats in the Vojvodina region (Republic of Serbia)Zorica Svircev, Slobodan B Marković, Jovan Vukadinov, et al.Medicinski Pregled|August 1, 2008
[On the development of the infectology service in Novi Sad]Grozdana Canak, Jovan Vukadinov, Snezana Brkić, et al.Gastroenterology|December 26, 2013
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis BScott Fung, Peter Kwan, Milotka Fabri, et al.Journal of Hepatology|August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised studyScott Fung, Peter Kwan, Milotka Fabri, et al.Pageof 2